Efficacy and tolerability of Helicobacter pylori eradication regimes in South Kivu, Eastern of the Democratic Republic of Congo: A single center observational study

Abstract

Background and AimsTreating Helicobacter pylori infections has become a major challenge due to increased antibiotic resistance. The aim of this study was to investigate the efficacy and tolerability of the main standard regimens recommended for H. pylori eradication in Bukavu, Eastern of the Democratic Republic of Congo.MethodsThe study enrolled patients with evidence of H. pylori infection in histological examination or serology testing combined with a positive fecal antigen test. As first‐line treatment, patients were randomized to either a 10‐days (OAC‐10) or a 14‐days (OAC‐14) regimen, employing a combination of omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily. In case of failure, a second line regimen was evaluated and included two others protocols: OAC‐10 regimen + levofloxacin 500 mg (OAC‐10+) and the bismuth‐based therapy (pantoprazole + bismuth salt + metronidazole + tetracycline) during 10 days. Our primary endpoint was H. pylori eradication and secondarily, the compliance and adverse effects were also evaluated.ResultsA total of 179 patients were enrolled. The eradication rate was 79.2% and 80.5% with the OAC‐10 and OAC‐14 regimen, respectively (p = 0.796). Adverse effects were significant higher in the OAC‐14 group than in the OAC‐10 group (36.5% vs. 57.8%; p < 0.001). On the other hand, the compliance rate was slightly higher in the OAC‐10 group (97.9% vs. 91.6%, p = 0.052) while clinical improvement was almost similar in both groups. Regarding the second line regimen, the bismuth‐based therapy (n = 18) seemed to show a better response with 100% of eradication rate and 100% of clinical improvement.ConclusionThe classic 10‐days triple therapy seems to be as effective as the 14‐days regimen while having in addition a good tolerance. Apart from cost issues, the bismuth‐based therapy seems to be a very good alternative in case of first‐line treatment failure.